Effectiveness and safety of everolimus in the treatment of autoimmune hepatitis related to anti-hepatitis C virus therapy after liver transplant: three case reports.
Identifieur interne : 001233 ( Main/Exploration ); précédent : 001232; suivant : 001234Effectiveness and safety of everolimus in the treatment of autoimmune hepatitis related to anti-hepatitis C virus therapy after liver transplant: three case reports.
Auteurs : T. Casanovas [Espagne] ; A. Argudo ; M C Pe A-CalaSource :
- Transplantation proceedings [ 1873-2623 ]
Descripteurs français
- KwdFr :
- Adulte d'âge moyen (MeSH), Antiviraux (effets indésirables), Association de médicaments (MeSH), Azathioprine (usage thérapeutique), Ciclosporine (usage thérapeutique), Cirrhose du foie (chirurgie), Cirrhose du foie (virologie), Femelle (MeSH), Humains (MeSH), Hépatite C (complications), Hépatite C (diagnostic), Hépatite C (traitement médicamenteux), Hépatite auto-immune (diagnostic), Hépatite auto-immune (traitement médicamenteux), Hépatite auto-immune (étiologie), Immunosuppresseurs (effets indésirables), Immunosuppresseurs (usage thérapeutique), Interférons (effets indésirables), Issue fatale (MeSH), Mâle (MeSH), Prednisone (usage thérapeutique), Ribavirine (effets indésirables), Récidive (MeSH), Résultat thérapeutique (MeSH), Sirolimus (analogues et dérivés), Sirolimus (effets indésirables), Sirolimus (usage thérapeutique), Tests de la fonction hépatique (MeSH), Transplantation hépatique (effets indésirables), Évérolimus (MeSH).
- MESH :
- analogues et dérivés : Sirolimus.
- chirurgie : Cirrhose du foie.
- diagnostic : Hépatite C, Hépatite auto-immune.
- effets indésirables : Antiviraux, Hépatite C, Immunosuppresseurs, Interférons, Ribavirine, Sirolimus, Transplantation hépatique.
- traitement médicamenteux : Hépatite C, Hépatite auto-immune.
- usage thérapeutique : Azathioprine, Ciclosporine, Immunosuppresseurs, Prednisone, Sirolimus.
- virologie : Cirrhose du foie.
- étiologie : Hépatite auto-immune.
- Adulte d'âge moyen, Association de médicaments, Femelle, Humains, Issue fatale, Mâle, Récidive, Résultat thérapeutique, Tests de la fonction hépatique, Évérolimus.
English descriptors
- KwdEn :
- Antiviral Agents (adverse effects), Azathioprine (therapeutic use), Cyclosporine (therapeutic use), Drug Therapy, Combination (MeSH), Everolimus (MeSH), Fatal Outcome (MeSH), Female (MeSH), Hepatitis C (complications), Hepatitis C (diagnosis), Hepatitis C (drug therapy), Hepatitis, Autoimmune (diagnosis), Hepatitis, Autoimmune (drug therapy), Hepatitis, Autoimmune (etiology), Humans (MeSH), Immunosuppressive Agents (adverse effects), Immunosuppressive Agents (therapeutic use), Interferons (adverse effects), Liver Cirrhosis (surgery), Liver Cirrhosis (virology), Liver Function Tests (MeSH), Liver Transplantation (adverse effects), Male (MeSH), Middle Aged (MeSH), Prednisone (therapeutic use), Recurrence (MeSH), Ribavirin (adverse effects), Sirolimus (adverse effects), Sirolimus (analogs & derivatives), Sirolimus (therapeutic use), Treatment Outcome (MeSH).
- MESH :
- chemical , adverse effects : Antiviral Agents, Immunosuppressive Agents, Interferons, Ribavirin, Sirolimus.
- chemical , analogs & derivatives : Sirolimus.
- chemical , therapeutic use : Azathioprine, Cyclosporine, Immunosuppressive Agents, Prednisone, Sirolimus.
- adverse effects : Liver Transplantation.
- complications : Hepatitis C.
- diagnosis : Hepatitis C, Hepatitis, Autoimmune.
- drug therapy : Hepatitis C, Hepatitis, Autoimmune.
- etiology : Hepatitis, Autoimmune.
- surgery : Liver Cirrhosis.
- virology : Liver Cirrhosis.
- Drug Therapy, Combination, Everolimus, Fatal Outcome, Female, Humans, Liver Function Tests, Male, Middle Aged, Recurrence, Treatment Outcome.
Abstract
Treatment of recurrent hepatitis C after liver transplantation is indicated in selected cases. During the combined treatment with pegylated interferon and ribavirin, some patients develop immune-mediated liver dysfunction similar to the previously described "de novo" autoimmune hepatitis. Herein we have presented three liver transplant patients who during or after combined antiviral treatment were diagnosed as autoimmune hepatitis related to interferon based on their clinical, biochemical, and liver histology features. There were two women and one man, of ages 49, 52, and 49 years who were transplanted due to cirrhosis related to hepatitis C virus genotype 1. In two patients, elevated liver enzymes occurred during antiviral therapy and in the third, after the therapy. The diagnosis of autoimmune hepatitis was reached after excluding other possible causes. One patient had a sustained viral response; and two cases were nonresponders. Antinuclear antibodies were present in two subjects and antinuclear antibodies and anti-smooth muscle antibodies in the other case. First-line treatment of autoimmune hepatitis with prednisone and azathioprine stabilized clinical and biochemical parameters'. In order to avoid the long-term use of prednisone, everolimus was introduced in the three patients. Interestingly, hepatitis C did not progress and clinical, biochemical, as well as histological parameters stabilized. In one patient, the liver fibrosis stage as assessed by histology showed improvement. However, one subject experienced repeated cerebral hemorrhage and died. Although this is heterogeneous population with partially known characteristics, with a difficult differential diagnosis, the objectives of preserving liver function and avoiding recurrent progressive hepatitis C seemed to be achieved by adding everolimus. In addition, we totally stopped prednisone therapy. In conclusion, treatment with everolimus in combination with cyclosporine achieved a partial remission in two liver transplan cases of autoimmune hepatitis related to interferon therapy.
DOI: 10.1016/j.transproceed.2011.05.028
PubMed: 21839242
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effectiveness and safety of everolimus in the treatment of autoimmune hepatitis related to anti-hepatitis C virus therapy after liver transplant: three case reports.</title><author><name sortKey="Casanovas, T" sort="Casanovas, T" uniqKey="Casanovas T" first="T" last="Casanovas">T. Casanovas</name><affiliation wicri:level="3"><nlm:affiliation>Unitat de Trasplantament Hepàtic, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, IDIBELL (Institut d'Investigació Biomèdica de Bellvitge), Barcelona, Spain. teresacasanovas@bellvitgehospital.cat</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Unitat de Trasplantament Hepàtic, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, IDIBELL (Institut d'Investigació Biomèdica de Bellvitge), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Argudo, A" sort="Argudo, A" uniqKey="Argudo A" first="A" last="Argudo">A. Argudo</name></author><author><name sortKey="Pe A Cala, M C" sort="Pe A Cala, M C" uniqKey="Pe A Cala M" first="M C" last="Pe A-Cala">M C Pe A-Cala</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011 Jul-Aug</date><idno type="RBID">pubmed:21839242</idno><idno type="pmid">21839242</idno><idno type="doi">10.1016/j.transproceed.2011.05.028</idno><idno type="wicri:Area/Main/Corpus">001263</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001263</idno><idno type="wicri:Area/Main/Curation">001263</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001263</idno><idno type="wicri:Area/Main/Exploration">001263</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effectiveness and safety of everolimus in the treatment of autoimmune hepatitis related to anti-hepatitis C virus therapy after liver transplant: three case reports.</title><author><name sortKey="Casanovas, T" sort="Casanovas, T" uniqKey="Casanovas T" first="T" last="Casanovas">T. Casanovas</name><affiliation wicri:level="3"><nlm:affiliation>Unitat de Trasplantament Hepàtic, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, IDIBELL (Institut d'Investigació Biomèdica de Bellvitge), Barcelona, Spain. teresacasanovas@bellvitgehospital.cat</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Unitat de Trasplantament Hepàtic, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, IDIBELL (Institut d'Investigació Biomèdica de Bellvitge), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Argudo, A" sort="Argudo, A" uniqKey="Argudo A" first="A" last="Argudo">A. Argudo</name></author><author><name sortKey="Pe A Cala, M C" sort="Pe A Cala, M C" uniqKey="Pe A Cala M" first="M C" last="Pe A-Cala">M C Pe A-Cala</name></author></analytic><series><title level="j">Transplantation proceedings</title><idno type="eISSN">1873-2623</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (adverse effects)</term><term>Azathioprine (therapeutic use)</term><term>Cyclosporine (therapeutic use)</term><term>Drug Therapy, Combination (MeSH)</term><term>Everolimus (MeSH)</term><term>Fatal Outcome (MeSH)</term><term>Female (MeSH)</term><term>Hepatitis C (complications)</term><term>Hepatitis C (diagnosis)</term><term>Hepatitis C (drug therapy)</term><term>Hepatitis, Autoimmune (diagnosis)</term><term>Hepatitis, Autoimmune (drug therapy)</term><term>Hepatitis, Autoimmune (etiology)</term><term>Humans (MeSH)</term><term>Immunosuppressive Agents (adverse effects)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Interferons (adverse effects)</term><term>Liver Cirrhosis (surgery)</term><term>Liver Cirrhosis (virology)</term><term>Liver Function Tests (MeSH)</term><term>Liver Transplantation (adverse effects)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Prednisone (therapeutic use)</term><term>Recurrence (MeSH)</term><term>Ribavirin (adverse effects)</term><term>Sirolimus (adverse effects)</term><term>Sirolimus (analogs & derivatives)</term><term>Sirolimus (therapeutic use)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen (MeSH)</term><term>Antiviraux (effets indésirables)</term><term>Association de médicaments (MeSH)</term><term>Azathioprine (usage thérapeutique)</term><term>Ciclosporine (usage thérapeutique)</term><term>Cirrhose du foie (chirurgie)</term><term>Cirrhose du foie (virologie)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Hépatite C (complications)</term><term>Hépatite C (diagnostic)</term><term>Hépatite C (traitement médicamenteux)</term><term>Hépatite auto-immune (diagnostic)</term><term>Hépatite auto-immune (traitement médicamenteux)</term><term>Hépatite auto-immune (étiologie)</term><term>Immunosuppresseurs (effets indésirables)</term><term>Immunosuppresseurs (usage thérapeutique)</term><term>Interférons (effets indésirables)</term><term>Issue fatale (MeSH)</term><term>Mâle (MeSH)</term><term>Prednisone (usage thérapeutique)</term><term>Ribavirine (effets indésirables)</term><term>Récidive (MeSH)</term><term>Résultat thérapeutique (MeSH)</term><term>Sirolimus (analogues et dérivés)</term><term>Sirolimus (effets indésirables)</term><term>Sirolimus (usage thérapeutique)</term><term>Tests de la fonction hépatique (MeSH)</term><term>Transplantation hépatique (effets indésirables)</term><term>Évérolimus (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term><term>Immunosuppressive Agents</term><term>Interferons</term><term>Ribavirin</term><term>Sirolimus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Sirolimus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Azathioprine</term><term>Cyclosporine</term><term>Immunosuppressive Agents</term><term>Prednisone</term><term>Sirolimus</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Liver Transplantation</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Sirolimus</term></keywords><keywords scheme="MESH" qualifier="chirurgie" xml:lang="fr"><term>Cirrhose du foie</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Hepatitis C</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Hepatitis C</term><term>Hepatitis, Autoimmune</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Hépatite C</term><term>Hépatite auto-immune</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hepatitis C</term><term>Hepatitis, Autoimmune</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiviraux</term><term>Hépatite C</term><term>Immunosuppresseurs</term><term>Interférons</term><term>Ribavirine</term><term>Sirolimus</term><term>Transplantation hépatique</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Hepatitis, Autoimmune</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Liver Cirrhosis</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hépatite C</term><term>Hépatite auto-immune</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Azathioprine</term><term>Ciclosporine</term><term>Immunosuppresseurs</term><term>Prednisone</term><term>Sirolimus</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Cirrhose du foie</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Liver Cirrhosis</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Hépatite auto-immune</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Therapy, Combination</term><term>Everolimus</term><term>Fatal Outcome</term><term>Female</term><term>Humans</term><term>Liver Function Tests</term><term>Male</term><term>Middle Aged</term><term>Recurrence</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Association de médicaments</term><term>Femelle</term><term>Humains</term><term>Issue fatale</term><term>Mâle</term><term>Récidive</term><term>Résultat thérapeutique</term><term>Tests de la fonction hépatique</term><term>Évérolimus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Treatment of recurrent hepatitis C after liver transplantation is indicated in selected cases. During the combined treatment with pegylated interferon and ribavirin, some patients develop immune-mediated liver dysfunction similar to the previously described "de novo" autoimmune hepatitis. Herein we have presented three liver transplant patients who during or after combined antiviral treatment were diagnosed as autoimmune hepatitis related to interferon based on their clinical, biochemical, and liver histology features. There were two women and one man, of ages 49, 52, and 49 years who were transplanted due to cirrhosis related to hepatitis C virus genotype 1. In two patients, elevated liver enzymes occurred during antiviral therapy and in the third, after the therapy. The diagnosis of autoimmune hepatitis was reached after excluding other possible causes. One patient had a sustained viral response; and two cases were nonresponders. Antinuclear antibodies were present in two subjects and antinuclear antibodies and anti-smooth muscle antibodies in the other case. First-line treatment of autoimmune hepatitis with prednisone and azathioprine stabilized clinical and biochemical parameters'. In order to avoid the long-term use of prednisone, everolimus was introduced in the three patients. Interestingly, hepatitis C did not progress and clinical, biochemical, as well as histological parameters stabilized. In one patient, the liver fibrosis stage as assessed by histology showed improvement. However, one subject experienced repeated cerebral hemorrhage and died. Although this is heterogeneous population with partially known characteristics, with a difficult differential diagnosis, the objectives of preserving liver function and avoiding recurrent progressive hepatitis C seemed to be achieved by adding everolimus. In addition, we totally stopped prednisone therapy. In conclusion, treatment with everolimus in combination with cyclosporine achieved a partial remission in two liver transplan cases of autoimmune hepatitis related to interferon therapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21839242</PMID><DateCompleted><Year>2012</Year><Month>01</Month><Day>05</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-2623</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>6</Issue><PubDate><MedlineDate>2011 Jul-Aug</MedlineDate></PubDate></JournalIssue><Title>Transplantation proceedings</Title><ISOAbbreviation>Transplant Proc</ISOAbbreviation></Journal><ArticleTitle>Effectiveness and safety of everolimus in the treatment of autoimmune hepatitis related to anti-hepatitis C virus therapy after liver transplant: three case reports.</ArticleTitle><Pagination><MedlinePgn>2233-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.transproceed.2011.05.028</ELocationID><Abstract><AbstractText>Treatment of recurrent hepatitis C after liver transplantation is indicated in selected cases. During the combined treatment with pegylated interferon and ribavirin, some patients develop immune-mediated liver dysfunction similar to the previously described "de novo" autoimmune hepatitis. Herein we have presented three liver transplant patients who during or after combined antiviral treatment were diagnosed as autoimmune hepatitis related to interferon based on their clinical, biochemical, and liver histology features. There were two women and one man, of ages 49, 52, and 49 years who were transplanted due to cirrhosis related to hepatitis C virus genotype 1. In two patients, elevated liver enzymes occurred during antiviral therapy and in the third, after the therapy. The diagnosis of autoimmune hepatitis was reached after excluding other possible causes. One patient had a sustained viral response; and two cases were nonresponders. Antinuclear antibodies were present in two subjects and antinuclear antibodies and anti-smooth muscle antibodies in the other case. First-line treatment of autoimmune hepatitis with prednisone and azathioprine stabilized clinical and biochemical parameters'. In order to avoid the long-term use of prednisone, everolimus was introduced in the three patients. Interestingly, hepatitis C did not progress and clinical, biochemical, as well as histological parameters stabilized. In one patient, the liver fibrosis stage as assessed by histology showed improvement. However, one subject experienced repeated cerebral hemorrhage and died. Although this is heterogeneous population with partially known characteristics, with a difficult differential diagnosis, the objectives of preserving liver function and avoiding recurrent progressive hepatitis C seemed to be achieved by adding everolimus. In addition, we totally stopped prednisone therapy. In conclusion, treatment with everolimus in combination with cyclosporine achieved a partial remission in two liver transplan cases of autoimmune hepatitis related to interferon therapy.</AbstractText><CopyrightInformation>Copyright © 2011 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Casanovas</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Unitat de Trasplantament Hepàtic, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, IDIBELL (Institut d'Investigació Biomèdica de Bellvitge), Barcelona, Spain. teresacasanovas@bellvitgehospital.cat</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Argudo</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Peña-Cala</LastName><ForeName>M C</ForeName><Initials>MC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transplant Proc</MedlineTA><NlmUniqueID>0243532</NlmUniqueID><ISSNLinking>0041-1345</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>49717AWG6K</RegistryNumber><NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>83HN0GTJ6D</RegistryNumber><NameOfSubstance UI="D016572">Cyclosporine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9008-11-1</RegistryNumber><NameOfSubstance UI="D007372">Interferons</NameOfSubstance></Chemical><Chemical><RegistryNumber>9HW64Q8G6G</RegistryNumber><NameOfSubstance UI="D000068338">Everolimus</NameOfSubstance></Chemical><Chemical><RegistryNumber>MRK240IY2L</RegistryNumber><NameOfSubstance UI="D001379">Azathioprine</NameOfSubstance></Chemical><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical><Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber><NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001379" MajorTopicYN="N">Azathioprine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016572" MajorTopicYN="N">Cyclosporine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068338" MajorTopicYN="N">Everolimus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017809" MajorTopicYN="N">Fatal Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019693" MajorTopicYN="N">Hepatitis, Autoimmune</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008111" MajorTopicYN="N">Liver Function Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016031" MajorTopicYN="N">Liver Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21839242</ArticleId><ArticleId IdType="pii">S0041-1345(11)00793-7</ArticleId><ArticleId IdType="doi">10.1016/j.transproceed.2011.05.028</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country><region><li>Catalogne</li></region><settlement><li>Barcelone</li></settlement></list><tree><noCountry><name sortKey="Argudo, A" sort="Argudo, A" uniqKey="Argudo A" first="A" last="Argudo">A. Argudo</name><name sortKey="Pe A Cala, M C" sort="Pe A Cala, M C" uniqKey="Pe A Cala M" first="M C" last="Pe A-Cala">M C Pe A-Cala</name></noCountry><country name="Espagne"><region name="Catalogne"><name sortKey="Casanovas, T" sort="Casanovas, T" uniqKey="Casanovas T" first="T" last="Casanovas">T. Casanovas</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001233 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001233 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:21839242
|texte= Effectiveness and safety of everolimus in the treatment of autoimmune hepatitis related to anti-hepatitis C virus therapy after liver transplant: three case reports.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21839242" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |